Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.57 |
| ▸ | GSK3B | P49841 | 12/20 | 0.56 |
| ▸ | PTPRC | P08575 | 2/20 | 0.42 |
| ▸ | S100A4 | P26447 | 1/20 | 0.41 |
| ▸ | GNG2 | P59768 | 1/20 | 0.40 |
| ▸ | GNB1 | P62873 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14705510 | 0.90 | PTPN1 (0.49) | PTPN1GSK3BPTPRCS100A4GNG2 | |
| SCHEMBL205280 | 0.80 | GSK3B (0.80) | PTPN1GSK3B | |
| SCHEMBL15105999 | 0.79 | SRD5A1 (0.54) | PTPN1GSK3BGNG2GNB1 | |
| SCHEMBL15106223 | 0.79 | NPC1 (0.58) | PTPN1GSK3BGNG2GNB1 | |
| SCHEMBL11482012 | 0.79 | PTPN1 (0.84) | PTPN1GSK3B | |
| SCHEMBL204586 | 0.78 | PTPN1 (0.49) | PTPN1GSK3B | |
| SCHEMBL14721244 | 0.78 | PTPN1 (0.49) | PTPN1GSK3BGNG2GNB1 | |
| SCHEMBL16891304 | 0.78 | PTPN1 (0.50) | PTPN1GSK3BGNG2GNB1 | |
| SCHEMBL14692626 | 0.78 | GSK3B (0.50) | PTPN1GSK3BGNG2GNB1 | |
| SCHEMBL10170998 | 0.77 | GSK3B (0.56) | GSK3BPTPRCS100A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140377223-A1 | SUBSTITUTED BIPHENYLENE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | SCHERING CORPORATION | 2014-12-25 | — | — | US | disclosed |
| US-20140377223-A1 | SUBSTITUTED BIPHENYLENE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | SCHERING CORPORATION | 2014-12-25 | — | — | US | disclosed |
| US-8889726-B2 | Chemica compounds | GLAXOSMITHKLINE LLC (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889726-B2 | Chemica compounds | GLAXOSMITHKLINE LLC (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140171476-A1 | Chemical Compounds | GLAXOSMITH KLINE LLC (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171476-A1 | Chemical Compounds | GLAXOSMITH KLINE LLC (US) | 2014-06-19 | — | — | US | disclosed |
| WO-2012018534-A2 | SUBSTITUTED BIPHENYLENE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | SCHERING CORPORATION (US) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171476-A1 | Chemical Compounds | SLC10A1, UGT2B7, CYP3A43 | PTPN1 1776/4885GSK3B 1312/4885PTPRC 994/4885 |
| US-20140377223-A1 | SUBSTITUTED BIPHENYLENE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | HAVCR2, CYP1B1, AHR | PTPN1 369/4885GSK3B 2132/4885PTPRC 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.